Outset Medical, Inc. (OM) stock
OMNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3071% below fair value
$3.86−0.31 (-7.43%)
Close on Nov 12, 2026Market cap $72.56MP/E –Yield –
Outset Medical r&d expenses
Research and development expenses are spending on new products and technology.
Outset Medical's R&D Expenses for the twelve months ending Sep 30, 2026 was $22.02M, down 8.5% year over year. For fiscal 2025 it was $21.24M, down 44.7% from the year before. The highest annual figure on record is $57.31M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.24M | -44.7% |
| FY2024 | Dec 31, 2024 | $38.40M | -33.0% |
| FY2023 | Dec 31, 2023 | $57.31M | +17.3% |
| FY2022 | Dec 31, 2022 | $48.86M | +33.0% |
| FY2021 | Dec 31, 2021 | $36.74M | +27.4% |
| FY2020 | Dec 31, 2020 | $28.85M | +23.7% |
| FY2019 | Dec 31, 2019 | $23.33M | +1.8% |
| FY2018 | Dec 31, 2018 | $22.92M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.90M | +9.7% |
| Q2 FY2026 | Jun 30, 2026 | $5.45M | +3.0% |
| Q1 FY2026 | Mar 31, 2026 | $5.62M | +1.9% |
| Q4 FY2025 | Dec 31, 2025 | $5.06M | -35.9% |
| Q3 FY2025 | Sep 30, 2025 | $5.38M | -33.9% |
| Q2 FY2025 | Jun 30, 2025 | $5.29M | -45.7% |
| Q1 FY2025 | Mar 31, 2025 | $5.52M | -56.4% |
| Q4 FY2024 | Dec 31, 2024 | $7.89M | -37.0% |
| Q3 FY2024 | Sep 30, 2024 | $8.14M | -49.4% |
| Q2 FY2024 | Jun 30, 2024 | $9.73M | -34.7% |
| Q1 FY2024 | Mar 31, 2024 | $12.64M | -8.4% |
| Q4 FY2023 | Dec 31, 2023 | $12.53M | +9.5% |
| Q3 FY2023 | Sep 30, 2023 | $16.08M | +23.1% |
| Q2 FY2023 | Jun 30, 2023 | $14.91M | +10.2% |
| Q1 FY2023 | Mar 31, 2023 | $13.79M | +27.3% |
| Q4 FY2022 | Dec 31, 2022 | $11.44M | +0.3% |
| Q3 FY2022 | Sep 30, 2022 | $13.06M | +34.2% |
| Q2 FY2022 | Jun 30, 2022 | $13.52M | +68.3% |
| Q1 FY2022 | Mar 31, 2022 | $10.83M | +43.1% |
| Q4 FY2021 | Dec 31, 2021 | $11.41M | +46.6% |
| Q3 FY2021 | Sep 30, 2021 | $9.73M | +6.0% |
| Q2 FY2021 | Jun 30, 2021 | $8.03M | +32.7% |
| Q1 FY2021 | Mar 31, 2021 | $7.57M | +29.7% |
| Q4 FY2020 | Dec 31, 2020 | $7.78M | +17.4% |
| Q3 FY2020 | Sep 30, 2020 | $9.18M | +60.7% |
| Q2 FY2020 | Jun 30, 2020 | $6.05M | – |
| Q1 FY2020 | Mar 31, 2020 | $5.84M | – |
| Q4 FY2019 | Dec 31, 2019 | $6.63M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.71M | – |
See a number that looks wrong?